JP2015506363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506363A5 JP2015506363A5 JP2014552326A JP2014552326A JP2015506363A5 JP 2015506363 A5 JP2015506363 A5 JP 2015506363A5 JP 2014552326 A JP2014552326 A JP 2014552326A JP 2014552326 A JP2014552326 A JP 2014552326A JP 2015506363 A5 JP2015506363 A5 JP 2015506363A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- composition according
- acceptable salt
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 7
- 230000001404 mediated Effects 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 5
- 206010003816 Autoimmune disease Diseases 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- 102100006827 EPRS1 Human genes 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010049752 Peau d'orange Diseases 0.000 claims 2
- 230000036232 cellulite Effects 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 208000006673 Asthma Diseases 0.000 claims 1
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010018651 Graft versus host disease Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 206010025135 Lupus erythematosus Diseases 0.000 claims 1
- 208000002780 Macular Degeneration Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 210000001577 Neostriatum Anatomy 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- 206010037075 Protozoal infection Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040925 Skin striae Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic Effects 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 201000008325 diseases of cellular proliferation Diseases 0.000 claims 1
- 108010092115 glutamyl-prolyl-tRNA synthetase Proteins 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000302 ischemic Effects 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000000056 organs Anatomy 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108010042589 prolyl T RNA synthetase Proteins 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 230000036573 scar formation Effects 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Claims (12)
- 下記式の化合物：
- 前記化合物は下記式の化合物：
- 前記化合物は下記式の化合物：
- 前記化合物は他のジアステレオマーを実質的に含まない、請求項１〜３のいずれか一項に記載の化合物。
- 請求項１〜４のいずれか一項に記載の化合物またはその薬学的に許容される塩；および任意選択的に薬学的に許容される賦形剤を含む医薬組成物。
- 請求項１〜４のいずれか一項に記載の化合物またはその塩；および任意選択的に化粧品として許容される賦形剤を含む化粧料組成物。
- グルタミル−プロリルｔＲＮＡシンテターゼを阻害するために用いる、請求項１〜４のいずれか一項に記載の化合物、または請求項５もしくは６に記載の組成物。
- Ｔｈ１７介在性状態、グルタミル−プロリルｔＲＮＡシンテターゼ介在性状態、またはＡＡＲ介在性状態を処置するための、請求項１〜４のいずれか一項に記載の化合物、または請求項５もしくは６に記載の組成物。
- 前記Ｔｈ１７介在性状態は自己免疫疾患、ドライアイ症候群、線維症、瘢痕形成、血管新生、虚血障害、炎症性疾患、神経変性疾患、セルライトおよび皮膚線条からなる群から選択される請求項８に記載の化合物または組成物。
- 移植用のドナー臓器を保護するための、請求項１〜４のいずれか一項に記載の化合物、または請求項５もしくは６に記載の組成物。
- 前記ＡＡＲ介在性状態は線維症、瘢痕形成、自己免疫疾患、ドライアイ症候群、移植片対宿主病、血管新生、癌、黄斑変性、脈絡膜血管新生、喘息、慢性炎症、循環器疾患、糖尿病、ウイルス感染、マラリア、原虫感染症、真菌感染、セルライト、多発性硬化症、関節リウマチ、ループス、乾癬、強皮症および皮膚線条からなる群から選択される、請求項８に記載の化合物または組成物。
- Ｔ細胞新生物を処置するための、請求項１〜４のいずれか一項に記載の化合物、または請求項５もしくは６に記載の組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261586271P | 2012-01-13 | 2012-01-13 | |
| US61/586,271 | 2012-01-13 | ||
| PCT/US2013/021223 WO2013106702A1 (en) | 2012-01-13 | 2013-01-11 | Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015506363A JP2015506363A (ja) | 2015-03-02 |
| JP2015506363A5 true JP2015506363A5 (ja) | 2016-03-03 |
Family
ID=47844437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014552326A Pending JP2015506363A (ja) | 2012-01-13 | 2013-01-11 | ハロフジノール誘導体、および化粧料組成物および医薬組成物におけるその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10155742B2 (ja) |
| EP (1) | EP2802572B1 (ja) |
| JP (1) | JP2015506363A (ja) |
| AU (1) | AU2013207796B2 (ja) |
| CA (1) | CA2861840C (ja) |
| HK (1) | HK1203947A1 (ja) |
| WO (1) | WO2013106702A1 (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9284297B2 (en) | 2008-08-11 | 2016-03-15 | President And Fellows Of Harvard College | Halofuginone analogs for inhibition of tRNA synthetases and uses thereof |
| JP2015506363A (ja) | 2012-01-13 | 2015-03-02 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ハロフジノール誘導体、および化粧料組成物および医薬組成物におけるその使用 |
| PT3159335T (pt) | 2014-06-23 | 2020-06-05 | Dae Woong Pharma | Novo composto heterocíclico |
| KR102277538B1 (ko) * | 2015-06-08 | 2021-07-14 | 주식회사 대웅제약 | 신규한 헤테로 고리 화합물, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
| JP2019196307A (ja) | 2016-09-15 | 2019-11-14 | 武田薬品工業株式会社 | 複素環アミド化合物 |
| US20190365760A1 (en) * | 2016-11-14 | 2019-12-05 | Keio University | A therapeutic or prophylactic agent for ischemic disease, glaucoma, optic nerve disease, retinal degenerative disease, angiogenic retinal disease, cancer, neurodegenerative or autoimmune disease, and a hypoxia inducing factor inhibitor |
| WO2019237125A1 (en) | 2018-06-08 | 2019-12-12 | The General Hospital Corporation | Inhibitors of prolyl-trna-synthetase |
| CN109134437B (zh) * | 2018-08-24 | 2021-05-25 | 中山大学 | 一种去氧常山酮类化合物及其制备方法和应用 |
| WO2021163304A1 (en) * | 2020-02-11 | 2021-08-19 | Tufts Medical Center, Inc. | Activation of neuropeptide receptors on plasmacytoid dendritic cells to treat or prevent ocular diseases associated with neovascularization and inflammation |
| AU2022316021A1 (en) * | 2021-07-23 | 2024-01-18 | Daewoong Pharmaceutical Co., Ltd. | Pharmaceutical composition for preventing or treating systemic sclerosis |
| WO2023140505A1 (ko) * | 2022-01-18 | 2023-07-27 | (주)큐라미스 | 할로푸지논을 유효성분으로 함유하는 신경퇴행성 또는 운동신경 질환 예방 또는 치료용 조성물 |
| CN114288300B (zh) * | 2022-01-29 | 2023-04-21 | 中国科学技术大学 | 常山酮在治疗和预防脂肪肝、肥胖的药物中的应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2694711A (en) | 1952-12-02 | 1954-11-16 | American Cyanamid Co | Quinazolone antimalarial compounds |
| US3320124A (en) | 1964-07-20 | 1967-05-16 | American Cyanamid Co | Method for treating coccidiosis with quinazolinones |
| DE2020234A1 (de) | 1970-04-25 | 1971-11-18 | Cassella Farbwerke Mainkur Ag | Basisch substituierte Derivate des 4(3H)-Chinazolinons |
| GB1541463A (en) | 1975-10-11 | 1979-02-28 | Lion Dentifrice Co Ltd | Process for prparing a multiple emulsion having a dispersing form of water-phase/oil-phase/water-phase |
| DE2934069A1 (de) | 1979-08-23 | 1981-03-12 | Hoechst Ag, 6000 Frankfurt | Mittel gegen theileriosen und seine verwendung. |
| US4762838A (en) | 1985-08-30 | 1988-08-09 | Pfizer Inc. | Quinazolin-4(3H)-one derivatives as anticoccidial agents |
| US4937370A (en) | 1987-06-02 | 1990-06-26 | The Procter & Gamble Company | Novel chromophores, sunscreen compositions and methods for preventing sunburn |
| US4999186A (en) | 1986-06-27 | 1991-03-12 | The Procter & Gamble Company | Novel sunscreen agents, sunscreen compositions and methods for preventing sunburn |
| US4725599A (en) | 1986-09-08 | 1988-02-16 | Pfizer Inc. | Heterocyclic ring fused pyrimidine-4 (3H)-ones as anticoccidial agents |
| US4960764A (en) | 1987-03-06 | 1990-10-02 | Richardson-Vicks Inc. | Oil-in-water-in-silicone emulsion compositions |
| US4800197A (en) | 1987-07-17 | 1989-01-24 | Richardson-Vicks Inc. | Anti-acne composition |
| US4891228A (en) | 1988-02-02 | 1990-01-02 | Richardson-Vicks Inc. | Medicated cleansing pads |
| US4891227A (en) | 1988-02-02 | 1990-01-02 | Richardson-Vicks Inc. | Medicated cleansing pads |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
| US5087445A (en) | 1989-09-08 | 1992-02-11 | Richardson-Vicks, Inc. | Photoprotection compositions having reduced dermal irritation |
| US6446032B1 (en) | 1990-09-21 | 2002-09-03 | Massachusetts Institute Of Technology | Designing compounds specifically inhibiting ribonucleic acid by binding to the minor groove |
| US5073371A (en) | 1990-11-30 | 1991-12-17 | Richardson-Vicks, Inc. | Leave-on facial emulsion compositions |
| US5073372A (en) | 1990-11-30 | 1991-12-17 | Richardson-Vicks, Inc. | Leave-on facial emulsion compositions |
| CA2113229C (en) | 1994-01-11 | 1999-04-20 | Mark Pines | Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof |
| US5759833A (en) | 1994-05-27 | 1998-06-02 | Cubist Pharmaceuticals, Inc. | Human isoleucyl-tRNA synthetase proteins, nucleic acids and tester strains comprising same |
| US20020025316A1 (en) | 1995-08-18 | 2002-02-28 | Ferguson Mark Williams James | Pharmaceutical composition containing inhibitors of interferon-gamma |
| US6028075A (en) | 1997-02-11 | 2000-02-22 | Pines; Mark | Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies |
| GB9702944D0 (en) | 1997-02-13 | 1997-04-02 | Univ Manchester | Reducing fibrosis |
| CA2285350A1 (en) | 1997-03-31 | 1998-10-08 | Hadasit Medical Research Services And Development Company Ltd. | Treatment for pulmonary fibrosis |
| EP1109559B1 (en) | 1998-08-13 | 2005-10-26 | Hadasit Medical Research Services & Development Co., Ltd. | Inhibition of pathogenic processes related to tissue trauma |
| ATE279175T1 (de) | 1999-08-20 | 2004-10-15 | Howard Murad | Pharmazeutische zusammensetzungen und verfahren zur verminderung des cellulite auftretens |
| ITMI991894A1 (it) | 1999-09-09 | 2001-03-09 | Carlo Ghisalberti | Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso |
| JP3771128B2 (ja) | 2000-12-28 | 2006-04-26 | 独立行政法人科学技術振興機構 | フェブリフジンおよびフェブリフジン化合物の新規合成方法 |
| US20050227935A1 (en) | 2001-05-18 | 2005-10-13 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA) |
| AU2002356043A1 (en) | 2001-08-14 | 2003-03-03 | Washington University In St. Louis | Systems and methods for screening pharmaceutical chemicals |
| WO2004069793A2 (en) | 2003-01-28 | 2004-08-19 | Bristol-Myers Squibb Company | Novel 2-substituted cyclic amines as calcium sensing receptor modulators |
| CN1263753C (zh) | 2004-05-21 | 2006-07-12 | 厦门大学 | 一种合成常山碱与ru－19110中间体的方法 |
| EP1855684A4 (en) | 2005-02-23 | 2011-04-06 | Collgard Biopharmaceuticals Ltd | PHARMACEUTICAL COMPOSITIONS OF THE ISOLATED D-ENANTIOMER OF THE CHINAZOLINONE DERIVATIVE HALOFUGINONE |
| WO2007058990A2 (en) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
| TWI464148B (zh) | 2006-03-16 | 2014-12-11 | Evotec Us Inc | 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途 |
| AU2007238816B2 (en) | 2006-04-10 | 2012-12-06 | President And Fellows Of Harvard College | Methods for modulating formation and progression of cellulite |
| KR20100110396A (ko) | 2006-04-14 | 2010-10-12 | 프라나 바이오테크놀로지 리미티드 | 연령 관련 황반 변성（에이엠디）의 치료 방법 |
| ES2474865T3 (es) | 2006-06-22 | 2014-07-09 | Prana Biotechnology Limited | Método de tratamiento de un tumor cerebral glioma |
| WO2008094909A2 (en) | 2007-01-29 | 2008-08-07 | Xenon Pharmaceuticals Inc. | Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions |
| US20080188498A1 (en) * | 2007-02-05 | 2008-08-07 | Radix Pharmaceuticals, Inc. | Pyridopyrimidinone compounds with antimalarial activity |
| CA2693062C (en) | 2007-06-21 | 2016-08-09 | Neuronascent, Inc. | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones |
| WO2009023267A2 (en) | 2007-08-15 | 2009-02-19 | President And Fellows Of Harvard College | Methods for modulating development and expansion of il-17 expressing cells |
| US20090123389A1 (en) | 2007-08-15 | 2009-05-14 | Malcolm Whitman | Methods for modulating Th17 cell development in the treatment and prevention of cellulite |
| US9284297B2 (en) | 2008-08-11 | 2016-03-15 | President And Fellows Of Harvard College | Halofuginone analogs for inhibition of tRNA synthetases and uses thereof |
| WO2010096170A2 (en) | 2009-02-19 | 2010-08-26 | President And Fellows Of Harvard College | Inhibition of trna synthetases and therapeutic applications thereof |
| US8357692B2 (en) * | 2010-06-20 | 2013-01-22 | Washington University | Methods of treatment of bone degenerative diseases |
| JP2015506363A (ja) | 2012-01-13 | 2015-03-02 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ハロフジノール誘導体、および化粧料組成物および医薬組成物におけるその使用 |
-
2013
- 2013-01-11 JP JP2014552326A patent/JP2015506363A/ja active Pending
- 2013-01-11 CA CA2861840A patent/CA2861840C/en active Active
- 2013-01-11 EP EP13708542.9A patent/EP2802572B1/en not_active Not-in-force
- 2013-01-11 WO PCT/US2013/021223 patent/WO2013106702A1/en active Application Filing
- 2013-01-11 US US14/371,934 patent/US10155742B2/en active Active
- 2013-01-11 AU AU2013207796A patent/AU2013207796B2/en not_active Ceased
-
2015
- 2015-05-12 HK HK15104491.9A patent/HK1203947A1/xx not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506363A5 (ja) | ||
| CY1125110T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| CY1119231T1 (el) | Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3 | |
| WO2017132432A8 (en) | Benzimidazole derivatives as modulators of ror-gamma | |
| JP2014176384A5 (ja) | ||
| JP2013032389A5 (ja) | ||
| JP2017537066A5 (ja) | ||
| JP2016530259A5 (ja) | ||
| RU2017128643A (ru) | Новое производное хинолина для применения в лечении и профилактике вирусных инфекций | |
| EA201690962A1 (ru) | Составы | |
| MD4666B1 (ro) | Inhibitori ai Syk | |
| JP2014221779A5 (ja) | ||
| JP2016540749A5 (ja) | ||
| PH12014502363A1 (en) | N-aryltriazole compounds as lpar antagonists | |
| TR201905814T4 (tr) | Jak inhibitörü olarak bipirazol tuzu. | |
| JP2016516808A5 (ja) | ||
| PH12014502789A1 (en) | N-alkyltriazole compounds as lpar antagonists | |
| NZ748966A (en) | Functionalized benzamide derivatives as antiviral agents against hbv infection | |
| WO2013160810A3 (en) | Novel betulinic acid derivatives as hiv inhibitors | |
| JP2014507477A5 (ja) | ||
| JP2015521195A5 (ja) | ||
| JP2015526455A5 (ja) | ||
| JP2017518982A5 (ja) |